1. Nature Japan
  2. Nature Biotechnology
  3. v34 n4
  4. 希少疾患療法の迅速承認の利用
Opinion and Comment

希少疾患療法の迅速承認の利用

Nature Biotechnology 34, 4 doi: 10.1038/nbt.3530

Improvements must be made to the qualification process for biomarkers as primary endpoints in pivotal clinical studies of treatments for the rarest of diseases.
Full text
PDF

目次へ戻る

advertisement
プライバシーマーク制度